Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib first-line treatment in advanced hepatocellular carcinoma with Child-Pugh class B liver function
2009-013870-42Phase 3Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sorafenib in hepatocellular carcinoma (HCC) (3 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Overall survival. Started Oct 2009; status: completed.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2009-013870-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013870-42.